Lupin gets USFDA nod to market Potassium Chloride capsules
Advertisement
New Delhi: Drug major Lupin has received final approval from the US health regulator to market Potassium Chloride extended release capsules, used to treat potassium deficiency in the body, in the American market.
The company has received final approval for its Potassium Chloride extended release capsules from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
"Lupin's US subsidiary, Lupin Pharmaceuticals Inc shall commence promoting the product in the US shortly," it added.
Lupin's product is the generic equivalent of Actavis Labs Inc's Potassium Chloride extended release capsules, which is indicated for the treatment of patients with hypokalemia.
According to IMS MAT September 2015 sales data, Potassium Chloride extended release capsules had US sales of USD 85.6 million.
The Mumbai-based firm has launched 8 products in the US market so far this fiscal, and received approvals for 18 from the USFDA.
The company has received final approval for its Potassium Chloride extended release capsules from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
"Lupin's US subsidiary, Lupin Pharmaceuticals Inc shall commence promoting the product in the US shortly," it added.
Lupin's product is the generic equivalent of Actavis Labs Inc's Potassium Chloride extended release capsules, which is indicated for the treatment of patients with hypokalemia.
According to IMS MAT September 2015 sales data, Potassium Chloride extended release capsules had US sales of USD 85.6 million.
The Mumbai-based firm has launched 8 products in the US market so far this fiscal, and received approvals for 18 from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.